GORTEC Announces New Trial Success for Head and Neck Cancer Treatment

TOURS, France, Jan. 7, 2025 /PRNewswire/

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 Trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as a post-operative Treatment component for resected patients with locally advanced squamous cell carcinoma of Head and Neck (LA-SCCHN), with high risk of relapse met its primary endpoint of Disease-Free survival (DFS) across all comers.  The study evaluated after surgery the addition of nivolumab to standard-of care (SOC) radiotherapy and cisplatin, compared to SOC radiotherapy and cisplatin alone. At a pre-determined number of DFS events, there was a statistically significant and clinically meaningful improvement in DFS for patients receiving nivolumab.Leggi su Liberoquotidiano.it